Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 84

SomaLogic swells series A round to $214m

The Novartis, Nan Fung, iCarbonX, Otsuka and Quest Diagnostics-backed proteomics technology developer has closed the second tranche of the round.

Dec 28, 2020

Singleron rings up $30m

Tencent led a series A2 round for the cell analysis technology developer that included Lilly Asia Ventures and Softbank China Venture Capital.

Dec 28, 2020

Nio Capital sees Fiture in $20m round

Nio Capital led the Tencent and Bertelsmann Asia Investments-backed home fitness technology developer's series A-plus round.

Dec 28, 2020

Magnax pushes ignition on $19.5m round

Magnax raised the cash from investors including automotive parts firm Hirschvogel Automotive with a view of broadening R&D and entering new markets with its EV motor technology.

Dec 24, 2020

Neomorph bonds $109m

Based on inventions from Harvard and Dana-Farber Cancer Institute, Neomorph was launched earlier this year with the support of Deerfield Management.

Dec 22, 2020

Xiangdao Chuxing checks in series A funding

Corporates Alibaba and CATL made strategic investments in SAIC's on-demand ride spinoff, through a $45.9m round preceding a planned geographic expansion.

Dec 19, 2020

Corporate venturing deal net: 14-18 December 2020

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Dec 18, 2020

Crehana creates space for more series A cash

Salesforce Ventures has taken part in the $17.5m close of the online learning platform developer's series A round, following a $4.5m first tranche early last year.

Dec 18, 2020

Daily deal net: December 18, 2020

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Dec 18, 2020

Neuron23 comes out of stealth with $114m

Biopharmaceutical company Origenis helped form the neurological and immunological disease drug developer, which has revealed series A and B funding.

Dec 18, 2020
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here